Jefferies Liftas PT on Celgene (CELG) to $114 Post Q4

Jefferies raised its price target on Celgene (NASDAQ: CELG) from $104 to $114 post Q4.

The firm comments, "On its 4Q earnings call, CELG focused details around achieving the 2017 guidance laid out earlier this month. We are raising our price target from $104 to $114 as we are adding modest apremilast to our valuation and raising our expectations for Abraxane penetration in pancreatic cancer following positive Phase 3 data released yesterday."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $97.49 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat